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Abstracts: Psoriasis and polycystic ovary syndrome (PCOS) are both triggered by hormones and chemical messengers. 
Psoriatic women are also more prone than the general population to PCOS, and both diseases are tightly associated 
with obesity, insulin resistance, diabetes, and metabolic and cardiovascular alterations. The aim of this paper is to review 
the current knowledge on the association between psoriasis and PCOS, from immunologic and genetic perspectives. 
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INTRODUCTION 
Psoriasis is a chronic immune-mediated 
inflammatory disease (IMID) that affects 2% of the 
general population. It is characterized by silver, scaly 
plaques on the extensor surfaces of the body, with 
different clinical manifestations. Genetic factors, 
immune dysregulation, and environmental factors are 
thought to be initial factors in the disease [1, 2]. Recent 
studies have shown that patients with IMIDs have a 
higher prevalence of comorbidities, including diabetes 
[3], cardiovascular disease [4], metabolic syndrome [4-
6], dyslipidemia [7], and nonalcoholic fatty liver disease 
[8-10].  
Polycystic ovary syndrome (PCOS) is a common 
disorder in women of reproductive age. Two of the 
following criteria are sufficient for diagnosis: oligo- or 
anovulation, biochemical or clinical hyperandrogenism, 
and polycystic ovaries on ultrasound examination [11]. 
Similar to psoriasis, the components of metabolic 
syndrome [12-14], obesity [13], diabetes [15], insulin 
resistance [16-20], dyslipidemia [21], hypertension [15, 
22-23], and coronary artery disease [15] are reported to 
be closely related to PCOS. Based on these 
similarities, with the support of the literature, female 
patients with psoriasis in the reproductive period are 
thought to have a higher risk of PCOS [24-26]. 
Although the common pathway that links psoriasis 
to PCOS is not known exactly, there are studies 
supporting this relationship. Moro et al. [26] first pointed 
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to the relationship between psoriasis and PCOS, 
reporting a higher risk of PCOS in about half of female 
psoriatic patients. Additionally, the women with 
psoriasis and PCOS had more insulin resistance, more 
hyperinsulinemia, and lower high-density lipoprotein 
(HDL) cholesterol levels compared to the patients with 
psoriasis alone. The etiology of these associations and 
findings are not clear, but common inflammatory 
mechanisms may have an influence [24, 26]. 
Genetic Factors 
Although triggering factors, such as streptococcal 
infections, mechanical and psychological trauma, and 
psychological stress, play an important role in initiating 
psoriasis, several studies have shown that there is a 
strong genetic predisposition involved with this disease. 
Approximately 35%–90% of patients report a positive 
family history. The concordance in monozygotic (70%) 
and dizygotic twins (20%) also supports the strong 
inherited property of psoriasis [27]. Today, psoriasis is 
accepted as a multifactorial disease influenced by 
several genes; thus, the pathogenesis of the disease is 
thought to result from immune dysregulation based on 
a genetic background [28-34]. Thirteen main 
chromosomal loci (PSORS1–13) have been identified 
as related to psoriasis. In particular, PSORS1 has been 
determined as the major gene, present in 50% of 
psoriatic patients. In addition, psoriasis can be defined 
as a polygenic inherited disease due to gene 
polymorphisms involved in both the immune system 
and in keratinocyte biology [35].  
PCOS also has an uncertain etiology. 
Environmental factors, molecular abnormalities, and 
genetic factors are thought to take part in its 
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etiopathogenesis. Familial clustering and twin studies 
have demonstrated that PCOS is a heritable disease, 
with up to 70% concordance in monozygotic twins [36]. 
A genome-wide association study (GWAS) provided 
evidence of associations between several single 
nucleotide polymorphisms and PCOS [19-21, 37].  
Several PCOS candidate genes are related to 
steroid hormone biosynthesis and metabolism [38-44], 
androgen synthesis and metabolism [44-45], and 
insulin and leptin metabolism.  
Psoriasis severity can be affected by female sex 
hormones and thus influenced by different hormonal 
phases (for example, puberty, postpartum, and 
menopause). Androgens are steroid structural 
hormones responsible for male characteristics. PCOS 
is a hyperandrogenic disorder, and hence experiments 
using animal models and cell lines related to androgen 
biosynthesis and metabolism have been widely 
performed to understand the molecular mechanisms 
[46-48]. Recent studies have demonstrated that PCOS 
is triggered not only by the androgen synthesis 
pathway, but also by androgen receptor-mediated 
pathways [44-46]. Udhane et al. [48] showed that 
retinoic acid receptor beta (RARB) enhanced androgen 
biosynthesis by stimulation of the genes responsible for 
androgen production (StAR, CYP17A1, HSD3B2). 
Retinoid acid derivatives (etretinate and its active 
metabolite, acitretin) are steroid structures used for the 
treatment of psoriasis. Thus, genetic and epigenetic 
variations in steroid and androgen synthesis pathways 
may trigger both psoriasis and PCOS [44].  
Adipose tissue is an endocrine organ that affects 
the metabolism via secreted cytokines and hormones. 
Both psoriasis and PCOS patients are more prone to 
developing obesity, and it is speculated that adipose 
tissue delivers cytokines that trigger PCOS in psoriatic 
patients, or vice versa. The phenotypic features of 
PCOS are associated with hyperinsulinemia as a result 
of insulin resistance [49] due to insulin secretion effects 
on ovarian androgen hypersecretion [50]. Recent 
studies have demonstrated that tandem repeat 
variations in the insulin gene (INS) [51-52], as well as 
single nucleotide polymorphisms in the insulin receptor 
(INSR) gene [19-20], are associated with PCOS. In 
addition, genetic alterations in insulin-mediated 
pathways cause insulin resistance, obesity, and 
metabolic and cardiovascular disease both in patients 
with psoriasis and in those with PCOS. The FTO and 
MC4R genes are related to obesity, pointing to their 
association with PCOS [53-55]. Fatty acid desaturase 
genes (FADS) were also found to be related to both 
dyslipidemia and PCOS [21]. 
Genes related to skin properties have also been 
analyzed in order to understand the mechanisms of 
psoriasis and PCOS. Li et al. [56] reported that the 
MTNR1B gene is related to type 2 diabetes mellitus, 
but not to PCOS susceptibility.  
The Role of Inflammation 
According to current studies, the main factor in the 
initiation of psoriasis is the cooperation of T cells, 
dendritic cells, and keratinocytes in the lesion area on 
the skin. T cells that are activated in psoriatic plaques 
are divided into two groups, Th1 (T helper) and Th2, 
depending on the cytokines they produce. Th1 is 
responsible for the production of inflammatory 
cytokines, while Th2 is responsible for non-
inflammatory cytokines [57]. Interleukin (IL)-23 and IL-
12, released from myeloid dendritic cells, activate T 
cells and lead to production of IL-17, IL-22, interferon 
(IFN)-γ, and tumor necrosis factor (TNF). IL-23, TNF, 
and IL-17 seem to be the key factors in psoriasis [58-
60].  
The primary reason for abnormal keratinocyte 
differentiation caused by keratinocyte hyperproliferation 
is that several cytokines and chemokines are secreted 
by antigen-presenting cells [61]. Cytokines such as IL-
6, IL-8, IL-18, IL-20, transforming growth factor (TGF)-
α, TGF-β, and amphiregulin (keratinocyte autocrine 
factor), secreted by keratinocytes, contribute to the 
course of psoriatic inflammation [62]. IFN-γ is a 
resoluble cytokine with antiviral, immune regulatory, 
and antineoplastic effects. It has been identified at high 
levels in psoriatic patients, and correlates with the 
severity of disease [63]. 
PCOS is currently accepted as a pro-inflammatory 
condition that induces low-grade inflammation. It 
results from ovarian dysfunction and fibrosis. IL-6 
levels are elevated in women with PCOS, yet the 
association with genetic variations in IL-6 and PCOS is 
controversial [64-66]. The association of the IL-6 
pathway and PCOS susceptibility may be related to 
testosterone-mediated IL-6 expression [67].  
TNF-α is a pro-inflammatory cytokine with a 
polypeptide structure, located at 6p21.3. It is 
multifunctional protein that affects lipid metabolism, 
insulin resistance, and endothelial function. Hence, pro-
inflammatory genotypes, such as encoding TNF-α and 
type 2 TNF receptors, play a role in the inflammatory 
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course of psoriasis and PCOS [64, 68-69], and TNF 
can trigger both PCOS [70] and psoriasis [62, 71-72]. 
In addition, TNF-α targeting may be useful for treating 
both PCOS [73] and psoriasis [74-76]. 
Associations With Other Diseases 
Psoriasis is regarded as a systemic condition, 
mainly because it is a chronic inflammatory disease 
strongly associated with metabolic and cardiovascular 
diseases. In recent years, several studies have 
reported a relationship between psoriasis and diabetes 
[77-79]. Additionally, studies investigating the link 
between cardiovascular disease and psoriasis have 
pointed to an increased risk for cardiovascular 
morbidity and mortality, and revealed that myocardial 
infarction is three times more common in psoriasis 
patients compared to the general population [80]. On 
the basis of the diseases accompanying psoriasis, 
metabolic pathways are the key factors in which 
cytokines play a role as mediator substances causing 
chronic inflammatory reactions. By causing 
inflammatory reactions, cytokines increase the risk of 
atherosclerosis and insulin resistance and ultimately 
lead to hypertension and type 2 diabetes mellitus [81].  
Psoriatic arthritis is a seronegative arthritis that 
occurs as a complication of psoriasis, with increased 
TNF-α production in the skin lesions and synovium of 
psoriatic patients during the cutaneous inflammation 
phase of the disease [82-83]. Similar to psoriasis, 
women with PCOS have a higher risk of metabolic 
disorders, such as obesity, dyslipidemia, diabetes 
mellitus, and insulin resistance [84]. 
DISCUSSION 
Psoriasis is a common immune-mediated skin 
disease, and PCOS is a common endocrine disorder in 
women of reproductive age. Although the clinical 
features of each disease are very different, the genetic 
background, chronic inflammatory process, and 
relationship to other metabolic disorders may all be 
signs of a link between PCOS and psoriasis. The 
association between the two diseases is not exactly 
known, but in recent studies, the prevalence of PCOS 
in patients with psoriasis has been found to be 
markedly higher than in the normal population. 
Furthermore, skin lesions are more exacerbated and 
the risk of insulin resistance, hyperinsulinemia, and low 
HDL levels are markedly higher when these two 
disorders coexist [14-16]. Various inflammatory 
markers, such as TNF-α, IFN-γ, IL-1, and IL-6, can 
have similar functions in the processes of both PCOS 
and psoriasis. Moro et al. suggested that anovulation, 
hyperandrogenism, and hyperinsulinemia contribute to 
the inflammatory process and worsen the features of 
psoriasis [24]. Consistent with this study, de Simone et 
al. [25] determined that the prevalence of PCOS was 
markedly higher in reproductive-age women with 
psoriasis, and this group was also at a higher risk of 
insulin resistance, high triglycerides, low HDL 
cholesterol, and more severe skin lesions [15]. 
Additionally, Bommsma et al. [85] reported poor 
pregnancy outcomes in women with PCOS, and due to 
these data, de Simone et al. [25] pointed to the 
probability of an important impact of psoriasis on the 
course of pregnancy, as well as the role of PCOS 
contributing to these effects.  
CONCLUSION 
PCOS is common in patients with psoriasis, and it 
has a negative impact on the clinical course of the 
disease. Genetic and inflammatory factors, and 
accompanying metabolic disorders, may contribute to 
this mechanism. Further studies are needed to clarify 
the exact etiology of PCOS, which will lead to a 
common treatment approach and better outcomes. 
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